Female infertility drug market to exhibit CAGR of 3.4 percent
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
List view / Grid view
News
Filter the results
DRC to use a second Ebola vaccine by November
The Democratic Republic of Congo will introduce a second Ebola vaccine next month to counter the outbreak of the disease in the country.
UK government signs contracts for medicine freight capacity
Four companies have agreed with the UK government to deliver medicines to the country after Brexit, signing contracts worth £86.6 million.
Sterile compounded drug products voluntarily recalled
Compounded drug products are being voluntarily recalled due a lack of sterility assurance.
Discover Nemera’s innovative technologies and end-to-end development offerings at booth 111C52
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health, including off-the-shelf innovative systems, customized design development and GMP contract manufacturing.
Breakthrough Therapy Designation granted to treatment for IDLs
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
DHSC supports continuity of medical supplies in a no-deal Brexit scenario
The Secretary of State for Health and Social Care is supporting the continuity of medical supplies if the UK is to leave the EU without a deal.
AI can predict which research will translate to clinical trials
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
Pharmaceutical product development within the Fujifilm Group
Custom manufacturing of specialty chemicals and APIs.
Johnson & Johnson ordered to pay $8bn in Risperdal case
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
Clinical trial shows cell therapy could be safe for liver disease patients
A new cell therapy has been tested in patients with liver cirrhosis and found no significant adverse effects.
First US state bans ‘pay-for-delay’ pharma practice
California’s state governor has signed a bill which will stop drug makers from paying generic drug producers to stay off the market.
Treatment to increase pain-free light exposure approved
The FDA has approved the first treatment to increase pain-free light exposure in patients with the rare disorder, erythropoietic protoporphyria.
MHRA announces recall of Zantac products made by GSK
The UK MHRA has issued an alert for the recall of unexpired Zantac products made by GSK due to the possible contamination of ranitidine in the medicines.
CQC registers UK clinic to prescribe medical cannabis
The CQC decision marks the first time the agency has accepted a clinic to prescribe patients with medical cannabis in the UK.